SCHEMBL5201739

SCHEMBL5201739

Cc1ccc(NC(=O)c2ccc(Cn3c(=O)[nH]n(C)c3=O)cc2)cc1Nc1nccc(-c2ccccc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 10/20 0.65
▸ ABL1 P00519 16/20 0.64
▸ KIT P10721 12/20 0.64
▸ BCR P11274 13/20 0.64
▸ PDGFRB P09619 4/20 0.64
▸ ABL2 P42684 3/20 0.64
▸ EGFR P00533 2/20 0.64
▸ PLK4 O00444 1/20 0.64
▸ DDX3X O00571 1/20 0.64
▸ GAK O14976 1/20 0.64
▸ SLC22A2 O15244 1/20 0.64
▸ MAPK13 O15264 1/20 0.64
▸ CA12 O43570 1/20 0.64
▸ SLC22A3 O75751 1/20 0.64
▸ ABCB11 O95342 1/20 0.64
▸ CA1 P00915 1/20 0.64
▸ CA2 P00918 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ ALB P02768 1/20 0.64
▸ RAF1 P04049 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067293 0.94 PDGFRA (0.75) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5201838 0.89 PDGFRA (0.55) PDGFRAABL1KITBCRPDGFRB
SCHEMBL27640742 0.85 PDGFRA (0.64) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5189023 0.84 PDGFRA (0.85) PDGFRAABL1KITBCRPDGFRB
SCHEMBL13437239 0.83 ABL1 (0.87) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5187795 0.83 PDGFRA (0.73) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5189147 0.82 ABL1 (0.64) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5205696 0.81 PDGFRA (0.62) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5204940 0.81 ABL1 (0.62) PDGFRAABL1KITBCRPDGFRB
SCHEMBL5202635 0.81 ABL1 (0.62) PDGFRAABL1KITBCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
US-7279576-B2 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-10-09 — — US disclosed
EP-1590344-A4 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2007-08-29 — — EP disclosed
EP-1590344-A2 ANTI-CANCER MEDICAMENTS Deciphera Pharmaceuticals, Inc. (US) 2005-11-02 — — EP disclosed
US-20040176395-A1 Anti-cancer medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-09 — — US disclosed
WO-2004060305-A2 ANTI-CANCER MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176395-A1 Anti-cancer medicaments ABL1, ABL2, SRC PDGFRA 565/4885ABL1 1/4885KIT 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback